ATE7574T1 - Antitumor-proteinhybrid und verfahren zu seiner herstellung. - Google Patents

Antitumor-proteinhybrid und verfahren zu seiner herstellung.

Info

Publication number
ATE7574T1
ATE7574T1 AT80302357T AT80302357T ATE7574T1 AT E7574 T1 ATE7574 T1 AT E7574T1 AT 80302357 T AT80302357 T AT 80302357T AT 80302357 T AT80302357 T AT 80302357T AT E7574 T1 ATE7574 T1 AT E7574T1
Authority
AT
Austria
Prior art keywords
sub
moiety
antitumor
ricin
indicates
Prior art date
Application number
AT80302357T
Other languages
English (en)
Inventor
Yasuhiko Masuho
Takeshi Hara
Original Assignee
Teijin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Limited filed Critical Teijin Limited
Application granted granted Critical
Publication of ATE7574T1 publication Critical patent/ATE7574T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT80302357T 1979-07-20 1980-07-11 Antitumor-proteinhybrid und verfahren zu seiner herstellung. ATE7574T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9163479A JPS5616418A (en) 1979-07-20 1979-07-20 Antitumor protein complex and its preparation
EP80302357A EP0023401B1 (de) 1979-07-20 1980-07-11 Antitumor-Proteinhybrid und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
ATE7574T1 true ATE7574T1 (de) 1984-06-15

Family

ID=14031960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT80302357T ATE7574T1 (de) 1979-07-20 1980-07-11 Antitumor-proteinhybrid und verfahren zu seiner herstellung.

Country Status (10)

Country Link
US (2) US4350626A (de)
EP (1) EP0023401B1 (de)
JP (1) JPS5616418A (de)
AT (1) ATE7574T1 (de)
AU (1) AU533793B2 (de)
CA (1) CA1163198A (de)
DE (1) DE3067935D1 (de)
FI (1) FI802278A7 (de)
HU (1) HU189469B (de)
IL (1) IL60609A (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
SE8102194L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0108764A1 (de) * 1982-05-11 1984-05-23 Genefusion S.A. Zellgiftiges mittel
ES522315A0 (es) * 1982-05-12 1984-08-16 Harvard College Un procedimiento para obtener una proteina hibrida.
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4448663A (en) * 1982-07-06 1984-05-15 The Dow Chemical Company Double L-shaped electrode for brine electrolysis cell
US4487715A (en) * 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
FR2550944B1 (fr) * 1983-08-23 1985-12-06 Sanofi Sa Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
EP0170697B1 (de) * 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxinkonjugate
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4670563A (en) * 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
JPS61132842U (de) * 1985-02-05 1986-08-19
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
DE3581210D1 (de) * 1985-03-04 1991-02-07 Dana Farber Cancer Inst Inc Immunotoxin und herstellung.
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
DE3688137D1 (de) * 1985-11-29 1993-04-29 Consolidated Pharmaceuticals L Ricin-antikoerper-konjugate.
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5395924A (en) * 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
WO1994002174A1 (fr) * 1992-07-28 1994-02-03 Toray Industries, Inc. Immunocomplexe
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US7175848B1 (en) 2000-09-22 2007-02-13 Board Of Regents, The University Of Texas System Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin
WO2001060393A1 (en) * 2000-02-16 2001-08-23 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
WO2003017938A2 (en) * 2001-08-22 2003-03-06 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
JP6823269B2 (ja) * 2016-06-20 2021-02-03 株式会社ＧｅｎＡｈｅａｄ Ｂｉｏ 抗体−薬物コンジュゲート

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319473A1 (de) * 1973-04-17 1974-11-07 Eisai Co Ltd Ricinhaltiges pharmazeutisches material mit antikrebswirkung
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4160018A (en) * 1973-06-25 1979-07-03 Bjorklund Knut B Stabilized cancer associated polypeptide antigen and preparation thereof
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4174385A (en) * 1976-10-08 1979-11-13 Robert Reid Method of identification of surface proteins of cancer cells, clinical test and method of immunization
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
DE2923787A1 (de) * 1979-06-12 1980-12-18 Max Planck Gesellschaft Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
US4296090A (en) * 1979-07-13 1981-10-20 Ortho Diagnostics, Inc. Anti-D test and reagent
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation

Also Published As

Publication number Publication date
FI802278A7 (fi) 1981-01-01
US4450154A (en) 1984-05-22
IL60609A0 (en) 1980-09-16
HU189469B (en) 1986-07-28
AU6044780A (en) 1981-01-22
CA1163198A (en) 1984-03-06
US4350626A (en) 1982-09-21
JPS5616418A (en) 1981-02-17
DE3067935D1 (en) 1984-06-28
EP0023401A3 (en) 1981-08-26
AU533793B2 (en) 1983-12-08
IL60609A (en) 1984-02-29
HUT34044A (en) 1985-01-28
EP0023401A2 (de) 1981-02-04
EP0023401B1 (de) 1984-05-23

Similar Documents

Publication Publication Date Title
ATE7574T1 (de) Antitumor-proteinhybrid und verfahren zu seiner herstellung.
ATE6937T1 (de) Hybridprotein gegen geschwuelste und verfahren zu seiner herstellung.
GB1148570A (en) N,n'-diglycidyl compounds and process for their manufacture and use
ES433437A1 (es) Procedimiento para la preparacion de beta-aminosilanos y beta-aminosiloxanos.
ES478156A1 (es) Un metodo de preparacion de compuestos heterociclicos derivados de hidantoina.
ES462003A1 (es) Procedimiento para la preparacion de compuestos de silicio y nitrogeno.
JPS55149331A (en) Modifier for synthetic resin
ES470274A1 (es) Procedimiento de preparacion de nuevos derivados de benzo- (b)-tienopiridinas
SE7602251L (sv) Omettade organiska kiselforeningar innehallande ketogrupper
FR2514006B1 (de)
UA40574C2 (uk) Похідні 17,20-епоксипрегнану, спосіб їх одержання, спосіб одержання похідних кортизону і проміжні сполуки
FR2356700A1 (fr) Pigments bis-azomethiniques metalliferes complexes
FR2390452A1 (fr) Derives fortimicine et leurs procedes de fabrication
SE8100074L (sv) Forfarande for framstellning av ett furanderivat
ES8102110A1 (es) Procedimiento para la preparacion de acido 1,2,3-tiadiazol- 5-il-tioglicolico
ES8301493A1 (es) Procedimiento para preparar polieteres sililados
GB1492380A (en) Substituted trithiolans and their use as flavouring agent
CH611601A5 (en) Process for the preparation of new cyclopentane derivatives
JPS5473785A (en) 2-alkyl-4-trimethyl-5-fluorouracil
ES209351A1 (es) Un procedimiento para la preparación de nuevos oxidiazolcompuestos
ES473091A1 (es) Un metodo para preparar compuestos heterociclicos nitrogena-dos
JPS548642A (en) Improvement in anticorrosion of electrodeposit coating film
ES420607A1 (es) Procedimiento para la obtencion de una composicion ectopa- rasiticida.
ES461695A1 (es) Procedimiento de preparar composiciones antraquinonicas an- ticancer
ES483796A1 (es) Un procedimiento para la preparacion de derivados del acido-penam-3-carboxilico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee